11月10日 - ** 医疗诊断公司 Guardant Health GH.O 股价盘前上涨 2.2% 至 98.82 美元
** 该公司称已扩大其 "Guardant Reveal血液检验 "的范围，这样医生就可以跟踪晚期实体瘤患者的治疗效果，而不需要组织样本
** 公司称，该检验能检测血液中的肿瘤信号，比扫描提前18个月显示治疗效果
** 免疫疗法研究显示，该测试比造影术提前五个月发现反应，与更好的治疗效果有关 - GH
** 公司在全线产品中增加了单击订购功能，以减轻医生的文书工作
** 截至上次收盘，该公司股价年累计上涨约 217
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.